Angelini Group - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Angelini Group - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Angelini Group - Product Pipeline Review - 2015', provides an overview of the Angelini Group's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Angelini Group's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Angelini Group including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Angelini Group's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Angelini Group's pipeline products

Reasons to Buy

- Evaluate Angelini Group's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Angelini Group in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Angelini Group's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Angelini Group and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Angelini Group
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Angelini Group and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Angelini Group Snapshot 5
Angelini Group Overview 5
Key Information 5
Key Facts 5
Angelini Group - Research and Development Overview 6
Key Therapeutic Areas 6
Angelini Group - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Angelini Group - Pipeline Products Glance 12
Angelini Group - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Angelini Group - Early Stage Pipeline Products 14
Discovery Products/Combination Treatment Modalities 14
Angelini Group - Drug Profiles 15
trazodone hydrochloride 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
prulifloxacin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Drug to Inhibit NAMPT for Pain and Inflammation 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Drug to Inhibit Prokineticin Receptor 1 for Pain and Inflammation 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Drugs to Inhibit Beta Lactamase for Bacterial Infections 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules to Inhibit GSK-3 Beta for CNS Disorders 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecules to Inhibit Gyrase and Topoisomerase IV for Infectious Diseases 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Angelini Group - Pipeline Analysis 23
Angelini Group - Pipeline Products by Target 23
Angelini Group - Pipeline Products by Route of Administration 24
Angelini Group - Pipeline Products by Molecule Type 25
Angelini Group - Pipeline Products by Mechanism of Action 26
Angelini Group - Recent Pipeline Updates 27
Angelini Group - Dormant Projects 28
Angelini Group - Company Statement 29
Angelini Group - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables

Angelini Group, Key Information 5
Angelini Group, Key Facts 5
Angelini Group - Pipeline by Indication, 2015 7
Angelini Group - Pipeline by Stage of Development, 2015 8
Angelini Group - Monotherapy Products in Pipeline, 2015 9
Angelini Group - Partnered Products in Pipeline, 2015 10
Angelini Group - Partnered Products/ Combination Treatment Modalities, 2015 11
Angelini Group - Pre-Registration, 2015 12
Angelini Group - Phase III, 2015 13
Angelini Group - Discovery, 2015 14
Angelini Group - Pipeline by Target, 2015 23
Angelini Group - Pipeline by Route of Administration, 2015 24
Angelini Group - Pipeline by Molecule Type, 2015 25
Angelini Group - Pipeline Products by Mechanism of Action, 2015 26
Angelini Group - Recent Pipeline Updates, 2015 27
Angelini Group - Dormant Developmental Projects,2015 28
Angelini Group, Subsidiaries 30